Over the past month, lawmakers in three states — Missouri, Colorado, and Mississippi — have introduced bills that would allow drug makers to promote their medicines for so-called off-label uses, so long as the information given to doctors is truthful.

The efforts come less than a year after Arizona adopted such a law, making it the first state in the U.S. to permit off-label promotion. The bills also arrive amid ongoing pressure on the Food and Drug Administration to loosen regulations for off-label promotions, which is one of the most contentious issues to roil both the agency and the pharmaceutical industry.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • It is very disturbing to be served an artcle only to realize I cannot finish reading it without incurring a 25 dollar fee or sign up for such. The info is available elsewhere and I will not search for it outside your source.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy